American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - A US multisite study
    Meeting Abstract

    Epperla, N.; Annunzio, K.; Shouse, G. P.; Grover, N. S.; Torka, P.; Watkins, M. P.; Anampa-Guzmán, A. C.; Oh, T. S.; Reves, H.; Tavakkoli, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • PROMMIS trial prospectively demonstrates the efficacy of SKY92 risk stratification in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Biran, N.; Dhakal, B.; Niesvizky, R.; Lentzsch, S.; McKay, J. T.; Vesole, D. H.; Nooka, A. K.; Paul, B.; Hari, P. N.; Stork-Sloots, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comparative analysis of clinical outcomes and healthcare resource utilization (HRU) in patients (pts) with newly diagnosed (nd) acute myeloid leukemia (aml) unfit for high-intensity chemotherapy treated with venetoclax (VEN) vs other therapies: Results from the AML real world evidence (ARC) initiative
    Meeting Abstract

    Desai, P.; Garcia, J. S.; Zeidner, J. F.; Abedin, S.; Wolach, O.; Vachhani, P.; Moshe, Y.; Pollyea, D. A.; Lai, C.; LeBlanc, T. W.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma treated with venetoclax: A multicenter retrospective analysis
    Meeting Abstract

    Sawalha, Y.; Sarosiek, S. R.; Welkie, R. L.; Seif, S.; Thapa, S.; Zanwar, S.; Cahill, K.; Treitman, R.; Shah, H.; Arora, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (liso-cel) in patients (pts) with R/R MCL: Subgroup analyses in pts with high-risk disease features from the MCL cohort of the TRANSCEND NHL 001
    Meeting Abstract

    Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M. A.; Hirayama, A. V.; Abramson, J. S.; Arnason, J. E.; Ghosh, N.; Mehta, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemias: Efficacy and safety results from the AUGMENT-101 phase 1/2 study
    Meeting Abstract

    Aldoss, I.; Issa, G. C.; Thirman, M. J.; DiPersio, J.; Arellano, M.; Blachly, J. S.; Mannis, G.; Perl, A.; Dickens, D.; McMahon, C. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • First results from a phase 1, first-in-human study of the Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies (BGB-16673-101)
    Meeting Abstract

    Seymour, J. F.; Cheah, C. Y.; Parrondo, R.; Thompson, M. C.; Stevens, D. A.; Lasica, M.; Wang, M. L.; Kumar, A.; Trotman, J.; Alwan, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of type of hypomethylating agent (HMA) used on outcomes of patients (pts) with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) - A large, multicenter, retrospective analysis
    Meeting Abstract

    Bewersdorf, J. P.; Kewan, T.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Safety and tolerability of Magrolimab combinations in patients with relapsed/refractory multiple myeloma (RRMM): Safety run-in results from a phase 2 Study
    Meeting Abstract

    Paul, B.; Minarík, J.; Cottini, F.; Gasparetto, C.; Khouri, J.; Gandhi, M.; Hillengass, J.; Levy, M.; Liedtke, M.; Manda, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Dexamethasone is associated with a lower incidence and severity of cytokine release syndrome compared with other corticosteroid regimens when given as premedication for glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)
    Meeting Abstract

    Falchi, L.; Carlo-Stella, C.; Morschhauser, F.; Dickinson, M.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N. L.; more...
    Blood (2023)

    Fulltext@MSK | Save